Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Employment agrmnt
|
|
Oncotelic Therapeutics, Inc. (MATN)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/23/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/18/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/13/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 07/13/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...|
Docs:
|
"SUBSCRIPTION AGREEMENT AND INVESTMENT LETTER",
"ONCOTELIC THERAPEUTICS, INC. COMMON STOCK PURCHASE WARRANT ________, 2023 THIS COMMON STOCK PURCHASE WARRANT of Oncotelic Therapeutics, Inc., a corporation duly organized and validly existing under the laws of Delaware , is issued to the Holder as part of a unit purchased by the Holder from the Company pursuant to which the Holder is also purchasing from the Company notes convertible into shares of its Common Stock, $0.01 par value per share warrants to purchase 250,000 Common Stock . FOR VALUE RECEIVED, the Company hereby certifies that the registered holder hereof, [●], with an address at [●], and the Holder’ s successors and assigns , is entitled to purchase from the Company [●] duly authorized, validly issued, fully paid and nonassessable shares of Common Stock, at a ...",
"Cover Page Interactive Data File (embedded within the Inline XBRL document)",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of __________, 2023, by and among Oncotelic Therapeutics, Inc. , a Delaware corporation with offices at 29397 Agoura Road, Suite 107, Agoura Hills, California 91301, and the investors signatories hereto . This Agreement is made pursuant to the Subscription Agreement and Investment Letter, dated as of the date hereof, executed by each of the Purchasers and the Company . NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged, the Company and the Purchasers agree as follows: 1. Definitio ns. Capitalized terms used and not otherwise defined herein that are defined in th..." |
|
| 06/30/2023 |
4
| Trieu Vuong (CHAIRMAN AND CEO) has filed a Form 4 on Oncotelic Therapeutics, Inc.|
Txns:
| Bought 425,000 shares
@ $0.021, valued at
$8.9k
Bought 75,000 shares
@ $0.026, valued at
$2k
|
|
| 06/16/2023 |
4
| Trieu Vuong (CHAIRMAN AND CEO) has filed a Form 4 on Oncotelic Therapeutics, Inc.|
Txns:
| Bought 400,000 shares
@ $0.0326, valued at
$13k
|
|
| 05/31/2023 |
4
| Trieu Vuong (CHAIRMAN AND CEO) has filed a Form 4 on Oncotelic Therapeutics, Inc.|
Txns:
| Bought 126,888 shares
@ $0.0341, valued at
$4.3k
|
|
| 05/19/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 05/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/02/2023 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/02/2023 |
4
| Trieu Vuong (CHAIRMAN AND CEO) has filed a Form 4 on Oncotelic Therapeutics, Inc.|
Txns:
| Bought 100,000 shares
@ $0.045, valued at
$4.5k
|
|
| 04/26/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 03/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 12/20/2022 |
8-K
| Quarterly results |
| 12/07/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/25/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/18/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/14/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 09/28/2022 |
4
| Trieu Vuong (CHAIRMAN AND CEO) has filed a Form 4 on Oncotelic Therapeutics, Inc.|
Txns:
| Bought 20,000 shares
@ $0.068, valued at
$1.4k
|
|
| 08/29/2022 |
4
| Trieu Vuong (CHAIRMAN AND CEO) has filed a Form 4 on Oncotelic Therapeutics, Inc.|
Txns:
| Bought 80,000 shares
@ $0.082, valued at
$6.6k
|
|
| 08/22/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/15/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 07/15/2022 |
8-K
| Quarterly results |
| 06/27/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
8-K
| Quarterly results |
| 06/03/2022 |
8-K
| Quarterly results |
| 05/23/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/16/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 05/11/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 05/09/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/26/2022 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
|
|
|